Barclays PLC Buys 65,188 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Barclays PLC increased its position in Acelyrin, Inc. (NASDAQ:SLRN) by 208.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 96,408 shares of the company’s stock after buying an additional 65,188 shares during the period. Barclays PLC owned 0.10% of Acelyrin worth $475,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in Acelyrin by 30.8% in the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after acquiring an additional 388,631 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Acelyrin by 566.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock worth $1,234,000 after purchasing an additional 212,758 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Acelyrin by 81.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock valued at $3,006,000 after purchasing an additional 273,604 shares during the period. Almitas Capital LLC bought a new stake in Acelyrin during the 2nd quarter valued at $1,659,000. Finally, Acuta Capital Partners LLC acquired a new position in Acelyrin during the third quarter worth $1,795,000. 87.31% of the stock is owned by institutional investors and hedge funds.

Acelyrin Price Performance

SLRN opened at $1.99 on Friday. Acelyrin, Inc. has a fifty-two week low of $1.91 and a fifty-two week high of $8.89. The firm has a market capitalization of $199.66 million, a P/E ratio of -0.81 and a beta of 1.94. The company’s 50-day moving average is $3.70 and its 200 day moving average is $4.76.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SLRN shares. HC Wainwright reduced their price objective on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Wells Fargo & Company cut their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, Citigroup lowered their price objective on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, Acelyrin currently has an average rating of “Hold” and an average target price of $9.60.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.